Overview

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Status:
Active, not recruiting
Trial end date:
2023-05-15
Target enrollment:
Participant gender:
Summary
Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis
Phase:
Phase 3
Details
Lead Sponsor:
Alvotech Swiss AG
Treatments:
Ustekinumab